Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Vascular Endothelial Growth Factor Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
BEVACIZUMAB 78,112 17,498 22.4% 23,114 3,229 61.1 yrs 55.0%
AFLIBERCEPT 26,891 8,527 31.7% 3,193 276 70.5 yrs 50.9%
RANIBIZUMAB 15,284 2,651 17.3% 2,265 204 71.7 yrs 52.5%
BEVACIZUMAB-MALY 121 20 16.5% 28 5 62.6 yrs 49.3%
BEVACIZUMAB-TNJN 18 0 N/A 11 1 58.7 yrs 22.2%

Head-to-Head Comparisons

BEVACIZUMAB vs AFLIBERCEPT BEVACIZUMAB vs RANIBIZUMAB BEVACIZUMAB vs BEVACIZUMAB-MALY BEVACIZUMAB vs BEVACIZUMAB-TNJN AFLIBERCEPT vs RANIBIZUMAB AFLIBERCEPT vs BEVACIZUMAB-MALY AFLIBERCEPT vs BEVACIZUMAB-TNJN RANIBIZUMAB vs BEVACIZUMAB-MALY RANIBIZUMAB vs BEVACIZUMAB-TNJN BEVACIZUMAB-MALY vs BEVACIZUMAB-TNJN
← Back to Vascular Endothelial Growth Factor Inhibitor [EPC] Class side effects →